Patent intelligence · US
US 11219604
Injectable sustained release composition and method of using the same for treating inflammation in joints and pain associated therewith
Injectable sustained release composition and method of using the same for treating inflammation in joints and pain associated therewith
Patent details — US 11219604
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jan 11, 2022
- Expiration
- Jan 6, 2042
- Applicant
- Eupraxia Pharmaceuticals USA LLC
- Claims
- 13
- CPC classes
- A61K, A61K31/56, A61K31/58, A61K9/0024
Quick answer
US 11219604 (Injectable sustained release composition and method of using the same for treating inflammation in joints and pain associated therewith) is held by Eupraxia Pharmaceuticals USA LLC. Status: granted. Granted Jan 11, 2022. Expires Jan 6, 2042 (15 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Eupraxia Pharmaceuticals USA LLC
- Grant date
- Expiration
- Claims
- 13
- CPC classes
- A61K, A61K31/56, A61K31/58, A61K9/0024, A61K9/5026, A61P
More from Eupraxia Pharmaceuticals USA LLC
Related pharmaceutical patents in our USPTO index.
Frequently asked questions
What is US patent 11219604?
US 11219604 (Injectable sustained release composition and method of using the same for treating inflammation in joints and pain associated therewith) is held by Eupraxia Pharmaceuticals USA LLC. Status: granted. Granted Jan 11, 2022. Expires Jan 6, 2042 (15 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11219604?
Eupraxia Pharmaceuticals USA LLC is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 3 pharmaceutical patents for this assignee.
When does US 11219604 expire?
Our index shows an expiration date of Jan 6, 2042 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.